JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Electrodiagnostic Biomarkers in Paraneoplastic Retinopathy

  • 0Department of Ophthalmology, Cantonal Hospital St. Gallen, Switzerland.
Klinische Monatsblatter Fur Augenheilkunde Und Fur Augenarztliche Fortbildung +

|

April 23, 2024

|

April 23, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Paraneoplastic retinopathy (PNR) causes rapid vision loss due to cancer. Diagnostic electrodiagnostic biomarkers were identified, aiding prompt PNR recognition and treatment evaluation.

Area Of Science

  • Ophthalmology
  • Oncology
  • Neuroscience

Background

  • Paraneoplastic retinopathy (PNR) is an autoimmune condition causing rapid vision loss.
  • It results from cross-reactivity between tumor antigens and retinal proteins.
  • Early diagnosis and treatment are crucial for preserving vision.

Purpose Of The Study

  • To identify electrodiagnostic biomarkers for diagnosing PNR.
  • To evaluate the effectiveness of treatments for PNR.

Main Methods

  • Retrospective observational case-controlled study.
  • Involved 25 patients with suspected PNR (11 diagnosed).
  • Utilized comprehensive ophthalmologic examinations and electrodiagnostic tests (ERG, mfERG).

Main Results

  • PNR patients exhibited central vision loss and retinal atrophy.
  • Electroretinography (ERG) showed severely attenuated responses.
  • Multifocal ERG (mfERG) revealed reduced central and paracentral responses.
  • Rituximab therapy showed potential in halting PNR progression.

Conclusions

  • Electrodiagnostic biomarkers can aid in the prompt recognition of PNR.
  • Investigating visual field deterioration in cancer patients for PNR is essential.
  • Therapeutic interventions may help manage PNR and preserve vision.